MX2021000900A - Forma cristalina de compuesto profarmaco de lanosterol y aplicacion de la misma. - Google Patents

Forma cristalina de compuesto profarmaco de lanosterol y aplicacion de la misma.

Info

Publication number
MX2021000900A
MX2021000900A MX2021000900A MX2021000900A MX2021000900A MX 2021000900 A MX2021000900 A MX 2021000900A MX 2021000900 A MX2021000900 A MX 2021000900A MX 2021000900 A MX2021000900 A MX 2021000900A MX 2021000900 A MX2021000900 A MX 2021000900A
Authority
MX
Mexico
Prior art keywords
application
crystal form
prodrug compound
lanosterol prodrug
lanosterol
Prior art date
Application number
MX2021000900A
Other languages
English (en)
Inventor
Xiaolin Li
Haiying He
Shuhui Chen
Jian Li
Zhi Luo
Yizhi Liu
Yandong Wang
Original Assignee
Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd filed Critical Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd
Publication of MX2021000900A publication Critical patent/MX2021000900A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a una forma cristalina de un compuesto de fórmula (I) y a una aplicación de la misma en la preparación de un fármaco para el tratamiento de una enfermedad oftálmica. (ver Fórmula).
MX2021000900A 2018-07-25 2019-07-25 Forma cristalina de compuesto profarmaco de lanosterol y aplicacion de la misma. MX2021000900A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810826425 2018-07-25
PCT/CN2019/097773 WO2020020306A1 (zh) 2018-07-25 2019-07-25 一种羊毛甾醇前药化合物的晶型及其应用

Publications (1)

Publication Number Publication Date
MX2021000900A true MX2021000900A (es) 2021-06-15

Family

ID=69180373

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000900A MX2021000900A (es) 2018-07-25 2019-07-25 Forma cristalina de compuesto profarmaco de lanosterol y aplicacion de la misma.

Country Status (16)

Country Link
US (1) US11149055B2 (es)
EP (1) EP3828193A4 (es)
JP (1) JP7046266B2 (es)
KR (1) KR20210038596A (es)
CN (1) CN112543762B (es)
AU (1) AU2019308940B2 (es)
BR (1) BR112021001172A2 (es)
CA (1) CA3107361C (es)
CO (1) CO2021000932A2 (es)
MA (1) MA53397A (es)
MX (1) MX2021000900A (es)
PH (1) PH12021550182A1 (es)
RU (1) RU2766088C1 (es)
SG (1) SG11202100665WA (es)
WO (1) WO2020020306A1 (es)
ZA (1) ZA202100923B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220133744A1 (en) * 2019-03-04 2022-05-05 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Composition of lanosterol prodrug compound, preparation method therefor and use thereof
KR20240046546A (ko) * 2021-08-18 2024-04-09 광저우 오쿠순 옵탈믹 바이오테크놀로지 캄파니 리미티드 스테로이드의 비문증 예방 및/또는 치료 약물 제조에 있어서의 용도
EP4389131A1 (en) * 2021-08-18 2024-06-26 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Pharmaceutical composition, preparation method therefor and application thereof
CN115737654A (zh) * 2021-09-03 2023-03-07 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
WO2023143452A1 (zh) * 2022-01-28 2023-08-03 广州润尔眼科生物科技有限公司 甾体化合物在预防和/或治疗白内障中的应用
WO2023147640A1 (en) * 2022-02-07 2023-08-10 GERVÁSIO ALVES DA SILVA, Társis Preparation of novel triterpene alcohol derivatives with enhanced bioavailability for cancer, inflammation and pain treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757062A (en) 1985-11-01 1988-07-12 E. I. Du Pont De Nemours And Company Substituted benzoate ester prodrugs of estrogens
DE3540702A1 (de) 1985-11-16 1987-05-21 Bayer Ag 1h-pyrido-(2,3-b) (1,4)-thiazine
RU2283318C1 (ru) 2005-02-24 2006-09-10 Любовь Степановна Ермолова Способ производства стеринов: ланостерола и холестерола из шерстного жира
SG11201701377YA (en) * 2014-08-22 2017-03-30 Kang Zhang Compositions and methods to treat vision disorders
WO2016029197A1 (en) * 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat and/or prevent vision disorders of the lens of the eye
AU2018212270B2 (en) * 2017-01-25 2020-07-02 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Lanosterol prodrug compound and preparation method therefor and use thereof

Also Published As

Publication number Publication date
PH12021550182A1 (en) 2022-02-21
US20210246158A1 (en) 2021-08-12
JP7046266B2 (ja) 2022-04-01
CA3107361C (en) 2022-03-22
WO2020020306A1 (zh) 2020-01-30
BR112021001172A2 (pt) 2021-04-27
EP3828193A4 (en) 2022-06-29
CN112543762A (zh) 2021-03-23
CO2021000932A2 (es) 2021-02-17
CA3107361A1 (en) 2020-01-30
JP2021524499A (ja) 2021-09-13
EP3828193A1 (en) 2021-06-02
SG11202100665WA (en) 2021-02-25
CN112543762B (zh) 2022-11-08
KR20210038596A (ko) 2021-04-07
US11149055B2 (en) 2021-10-19
AU2019308940B2 (en) 2024-02-08
MA53397A (fr) 2021-06-02
ZA202100923B (en) 2021-10-27
AU2019308940A1 (en) 2021-03-11
RU2766088C1 (ru) 2022-02-07

Similar Documents

Publication Publication Date Title
PH12021550182A1 (en) Crystal form of lanosterol prodrug compound and application thereof
MX2018010192A (es) Inhibidores de glucosidasa.
ZA201701299B (en) Glycosidase inhibitors
MX2018010191A (es) Inhibidores de glucosidasa.
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
PH12018501920A1 (en) Bromodomain inhibitors
MX2021008583A (es) Composiciones para el tratamiento de trastornos del snc.
GEP20207160B (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
NZ725008A (en) Compounds for treating spinal muscular atrophy
MX2016007440A (es) Inhibidores del bromodominio.
MX2019010085A (es) Inhibidores de la glicosidasa de sulfoximina.
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
MX2017015740A (es) Moduladores de ror gamma (ror?).
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
MX2017015741A (es) Moduladores de ror gamma (ror?).
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2017015739A (es) Moduladores de ror gamma (ror?).
EA202090414A1 (ru) Соединения и их применение
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
SA521431279B1 (ar) D1 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
CY1122418T1 (el) Αγωγη ερυθρομελαλγιας
PH12018502680A1 (en) Crystal forms of 9-aminomethyl substituted tetracycline compound and preparation method thereof